Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | RXRG | P48443 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036683 | 0.90 | FFAR4 (0.61) | MKNK1MKNK2FFAR4FFAR1LMNA | |
| SCHEMBL6069860 | 0.88 | P4HTM (0.58) | FFAR4FFAR1LMNANPC1PKM | |
| SCHEMBL29886594 | 0.88 | P4HTM (0.58) | FFAR4FFAR1LMNANPC1PKM | |
| SCHEMBL1842380 | 0.87 | MKNK1 (0.55) | MKNK1MKNK2FFAR4LMNANPC1 | |
| SCHEMBL31689010 | 0.85 | FFAR1 (0.56) | MKNK1MKNK2FFAR4FFAR1LMNA | |
| SCHEMBL3769640 | 0.81 | MAP3K11 (0.60) | — | |
| SCHEMBL14466730 | 0.80 | MKNK1 (0.51) | MKNK1MKNK2LMNANPC1PKM | |
| SCHEMBL27513663 | 0.79 | FFAR4 (0.58) | FFAR4FFAR1LMNANPC1PKM | |
| SCHEMBL4039531 | 0.79 | FFAR4 (0.55) | MKNK1MKNK2FFAR4LMNANPC1 | |
| SCHEMBL15265573 | 0.78 | FFAR4 (0.74) | FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101528691-B | Matrix metalloproteinase inhibitors | RANBAXY LAB LTD | 2014-11-26 | — | — | CN | disclosed |
| US-8846910-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-09-30 | — | — | US | disclosed |
| US-8816073-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-08-26 | — | — | US | disclosed |
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-14 | — | — | US | disclosed |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-07 | — | — | US | disclosed |
| US-8507670-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2013-08-13 | — | — | US | disclosed |
| EP-2074093-B1 | PROCESS FOR PREPARING MATRIX METALLOPROTEINASE INHIBITORS AND CHIRAL AUXILIARY THEREFOR | RANBAXY LAB LTD (IN) | 2012-10-10 | — | — | EP | disclosed |
| EP-2474531-A2 | Matrix metalloproteinase inhibitors | Ranbaxy Laboratories Limited (IN) | 2012-07-11 | — | — | EP | disclosed |
| EP-2322507-A1 | Matrix metalloproteinase inhibitors | Ranbaxy Laboratories Limited (IN) | 2011-05-18 | — | — | EP | disclosed |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2010-04-01 | — | — | US | disclosed |
| CN-101528691-A | Matrix metalloproteinase inhibitors | RANBAXY LAB LTD (IN) | 2009-09-09 | — | — | CN | disclosed |
| EP-2074093-A2 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008023336-A2 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | MKNK1 2892/4885MKNK2 3521/4885FFAR4 1216/4885 |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | MKNK1 2892/4885MKNK2 3521/4885FFAR4 1216/4885 |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP12 | MKNK1 2918/4885MKNK2 3569/4885FFAR4 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.